Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 203.3%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 15th total of 6,100 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is presently 1.7 days. Approximately 0.2% of the shares of the stock are sold short.

Armata Pharmaceuticals Stock Down 1.0 %

Shares of NYSEAMERICAN:ARMP opened at $2.00 on Thursday. The company has a market cap of $72.36 million, a P/E ratio of -1.22 and a beta of 0.78. Armata Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $4.48.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.